GL Stock Analysis — Globe Life
Sector: Financials
AI Verdict
At 9.6x forward earnings with nearly 10% growth expected, this is cheap for the growth you're getting if Globe Life's direct distribution moat keeps delivering.
Competitive Moat
Globe Life specializes in life and supplemental health insurance for middle-income Americans, using direct-to-consumer distribution that reduces reliance on third-party agents. Their entrenched agent network and focus on underserved markets create a durable customer acquisition advantage.
Summary
Globe Life trades at just 9.6x forward earnings, making it one of the cheapest names in insurance with nearly double-digit EPS growth expected.
Where It Stands
The stock is up 24.81% over the past year, RSI sits at a neutral 46.8, and the forward P/E of 9.6x is a steep discount to the financial sector's 14x median.
Key Metrics
- RSI: 46.8 — Neutral
- Trailing P/E: 10.5x
- Forward P/E: 9.6x
- PEG Ratio: 1.01
- Earnings Growth: +0.1%
- Revenue Growth: +0.0%
- Market Cap: $11.9B
- Dividend Yield: 0.01%
- 1-Year Return: 24.81%
- 52-Week High: $157.92
- 52-Week Low: $116.73
Analyst Consensus
18 Buy · 5 Hold · 0 Sell (23 analysts)
Bull Case
You're paying just 9.6x next year's earnings for 9.7% expected EPS growth, which is cheap for the growth on offer in a sector where many peers trade at much higher multiples.
Bear Case
If the P/E multiple reverts from 9.6x up to the sector median of 14x, the stock could see a sharp re-rating, but if growth disappoints, even a neutral RSI of 46.8 offers limited technical support.
Catalyst to Watch
Watch for quarterly earnings beats or guidance raises, as any upside surprise to the 9.7% EPS growth expectation could trigger a multiple re-rating.